The human papilloma virus testing market is projected to grow from USD 2.0 billion in 2025 to USD 7.5 billion by 2035, at a CAGR of 14.1%. Cervical Cancer Screening will dominate with a 76.7% market share, while consumables will lead the product outlook segment with a 65.3% share.